We evaluated fadraciclib, a CDK2/CDK5/CDK9 inhibitor which has successfully completed a First-in-Human Phase I clinical trial, and is continuing clinical development in both solid tumors and hematological malignancies. Here, CDK5 is linked to hematologic disorder.